CCD 3693

Drug Profile

CCD 3693

Alternative Names: CO 32693

Latest Information Update: 23 Dec 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Purdue Pharma
  • Class Sleep disorder therapies
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insomnia

Most Recent Events

  • 23 Dec 2002 Discontinued - Phase-I for Insomnia in Europe (unspecified route)
  • 13 Aug 1998 Agreement between CoCensys and Searle to collaborate on development of CCD 3693 has been terminated
  • 06 Mar 1998 Phase-I clinical trials for Insomnia in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top